Repositorio Dspace

Perioperative chemotherapy and long-term cure in resected grade 3 gastroenteropancreatic neuroendocrine carcinomas: The GETNE SOUTH-NEC Study

Mostrar el registro sencillo del ítem

dc.contributor.author Carmona-Bayonas, Alberto
dc.contributor.author Jiménez-Fonseca, Paula
dc.contributor.author Capdevila, Jaume
dc.contributor.author Alonso, Vicente
dc.contributor.author Benavent, Marta
dc.contributor.author López-López, Carlos
dc.contributor.author Ruffinelli, José-Carlos
dc.contributor.author Crespo, Guillermo
dc.contributor.author Nosti, Laura
dc.contributor.author San-Roman-Gil, María
dc.contributor.author Marín-Zafra, Gema-Rocío
dc.contributor.author Hernando, Jorge
dc.contributor.author Azpiroz, Mónica-Marazuela
dc.contributor.author Castano, Angel
dc.contributor.author García-Carbonero, Rocio
dc.date.accessioned 2026-11-11T09:07:22Z
dc.date.available 2026-11-11T09:07:22Z
dc.date.issued 2026-11
dc.identifier.citation Carmona-Bayonas A, Jimenez-Fonseca P, Capdevila J, Alonso V, Benavent M, Lopez-Lopez C, et al. Perioperative chemotherapy and long-term cure in resected grade 3 gastroenteropancreatic neuroendocrine carcinomas: The GETNE SOUTH-NEC Study. European Journal of Cancer. noviembre de 2026;248:117773. doi:10.1016/j.ejca.2026.117773
dc.identifier.issn 0959-8049
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/29208
dc.description.abstract BACKGROUND: In resected stage I-III gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC), whether perioperative chemotherapy eradicates residual disease or merely delays relapse is unknown, since Cox models cannot distinguish these effects. METHODS: We analysed 162 patients with resected stage I-III GEP-NEC from the GETNE registry. Event-free (EFS), recurrence-free (RFS) and overall survival (OS) were modeled by Cox regression with chemotherapy as a time-dependent exposure, adjusted for age, sex, performance status, stage, Ki-67 and site, and by a Bayesian promotion-time cure model that separates a clonogenic (cure) component from a kinetic (relapse timing) component. RESULTS: Seventy-four patients (46%) received chemotherapy; median follow-up was 93 months. Chemotherapy was associated with longer EFS (hazard ratio [HR], 0.61; 95% confidence interval [CI], 0.40-0.96) and RFS (HR, 0.59; 95% CI, 0.37-0.93), but not clearly with OS (HR, 0.73; 95% CI, 0.46-1.15). On EFS, the cure model attributed the association to a lower clonogenic burden (ratio, 0.67; 95% credible interval [CrI], 0.40-1.11; posterior probability, 94%) rather than to slower kinetics (ratio, 0.93); on RFS both components contributed. The population cure fraction was 22.7% (95% CrI, 15.9-29.6) for EFS and 28.6% (21.9-35.7) for RFS, matching the Kaplan-Meier plateaus. No Ki-67 by chemotherapy interaction was detected. CONCLUSION: In resected grade 3 GEP-NEC, perioperative chemotherapy is associated with longer EFS and RFS and, on the composite endpoint, with a higher probability of long-term cure rather than delayed recurrence. These associations are observational and the cure-versus-delay decomposition is descriptive. Cure models add information beyond conventional survival metrics.
dc.language.iso eng
dc.publisher ELSEVIER SCI LTD
dc.rights Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internaciona
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es *
dc.subject.mesh Humans
dc.subject.mesh Female
dc.subject.mesh Male
dc.subject.mesh Pancreatic Neoplasms/pathology/drug therapy/mortality/surgery
dc.subject.mesh Middle Aged
dc.subject.mesh Aged
dc.subject.mesh Carcinoma, Neuroendocrine/pathology/drug therapy/mortality/surgery
dc.subject.mesh Intestinal Neoplasms/pathology/drug therapy/mortality/surgery
dc.subject.mesh Stomach Neoplasms/pathology/drug therapy/mortality/surgery
dc.subject.mesh Chemotherapy, Adjuvant
dc.subject.mesh Neoplasm Grading
dc.subject.mesh Antineoplastic Combined Chemotherapy Protocols/therapeutic use
dc.subject.mesh Adult
dc.subject.mesh Time Factors
dc.subject.mesh Registries
dc.subject.mesh Neoplasm Recurrence, Local
dc.subject.mesh Neuroendocrine Tumors
dc.title Perioperative chemotherapy and long-term cure in resected grade 3 gastroenteropancreatic neuroendocrine carcinomas: The GETNE SOUTH-NEC Study
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 42869860
dc.relation.publisherversion https://linkinghub.elsevier.com/retrieve/pii/S0959804926015558
dc.type.version info:eu-repo/semantics/publishedVersion
dc.identifier.doi 10.1016/j.ejca.2026.117773
dc.journal.title European Journal of Cancer
dc.identifier.essn 1879-0852


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internaciona Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internaciona

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta